TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6105520
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (high dose)
Study: 6105520
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (intravenous infusion)
Study: 6105520
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (intravenous infusion)
Study: 26603627
Drug: Loss-framed message
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss-framed message promoting calcium supplements
Study: 20806117
Drug: Apixaban 20
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 20 mg once daily
Study: 15822418
Drug: Sufentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil TCI (0.08-0.1 ng/ml)
Study: 15822418
Drug: i.v. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. morphine (Bolus group)
Study: 11337713
Drug: Ropivacaine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 75 mg in 20 mL of saline solution
Study: 11337713
Drug: Morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2 mg in 20 mL of saline solution
Study: 11337713
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 20 mL
Study: 181258
Drug: Intravenous Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Intralipid
Study: 181258
Drug: Intravenous egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous egg phospholipid
Study: 30910373
Drug: NAE (Net
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAE (Net Acid Excretion) measurement
Study: 30910373
Drug: Insulin resistance,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin resistance, dietary potential renal acid load, and metabolically active medications (e.g., metformin, allopurinol, nonstatin lipid agents)
Study: 16688811
Drug: 3‐DCRT combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐DCRT combined with FOLFOX4 chemotherapy
Study: 11304939
Drug: Dimetindene 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimetindene 0.1% (Fenistil Nasal Spray)
Study: 11304939
Drug: Levocabastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine 0.05% solution
Study: 9322630
Drug: Active management
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active management of labor with epidural analgesics
Study: 9322630
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care control protocol with epidural analgesics
Study: 8140565
Drug: Hydrochlorothiazide (E)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (E) 25‐50 mg per day
Study: 8140565
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of altizide 15 mg and aldactone 25 mg (A) 1 or 2 tablets per day
Study: 31311674
Drug: Rimegepant (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant (75 mg orally disintegrating tablet)
Study: 8767563
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg clorazepate dipotassium
Study: 1684196
Drug: Ciprofloxacin (iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (iv or oral)
Study: 6356321
Drug: Sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1 g four times daily
Study: 6356321
Drug: Cimetidine, 200
Normalized name: Cimetidine, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 200 mg three times daily and 400 mg at night
Study: 28924075
Drug: Physiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy plus 30 mg/day edoxaban
Study: 16628625
Drug: 30-mg clevudine
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg clevudine
Study: 16628625
Drug: 50-mg clevudine
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg clevudine
Study: 4909360
Drug: Phenobarbitone (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (administered orally for 3 days)
Study: 4909360
Drug: Placebo linctus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo linctus (administered orally for 3 days)
Study: 22417197
Drug: FRIENDS for
Normalized name: Aluminum Zirconium Tetrachlorohydrex GLY 17.8 g in 100 g TOPICAL STICK [DEGREE GIRL FRIENDS FOREVER ANTIPERSPIRANT AND DEODORANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRIENDS for life program (manualized individual cognitive behavioral treatment)
Study: 20861377
Drug: Hydrocortisone administered
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone administered 75 min before scanning
Study: 20861377
Drug: Hydrocortisone administered
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone administered 285 min before scanning
Study: 15853098
Drug: Ca(OH)2 solution
Normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 solution
Study: 10435146
Drug: Oral Balance
Normalized name: Biotene Oral Balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Balance gel and Biotene toothpaste
Study: 10435146
Drug: Placebo (carboxymethylcellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (carboxymethylcellulose gel and commercial toothpaste)
Study: 7852526
Drug: 0.05 mg/kg.day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg.day gallium nitrate
Study: 7852526
Drug: 0.25 mg/kg.day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg.day gallium nitrate
Study: 7852526
Drug: 0.5 mg/kg.day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg.day gallium nitrate
Study: 2087618
Drug: Nifluril (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifluril (400 mg daily, morniflumate)
Study: 2087618
Drug: Amoxicilline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicilline (50 mg/kg daily)
Study: 358728
Drug: Rivanol combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivanol combined with half dose PGF2alpha
Study: 26489835
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) twice daily for 2 weeks at 30% of maximal inspiratory pressure, in addition to standard postoperative physiotherapy.
Study: 22339611
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and SSRIs
Study: 20730073
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Candesartan and CCBs)
Study: 11892706
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg BID for 6 weeks (OA)
Study: 11892706
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg BID or TID for 6 weeks (OA)
Study: 11892706
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg BID for 24 weeks (RA)
Study: 11892706
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg BID for 24 weeks (RA)
Study: 10333347
Drug: valsartan 10
Normalized name: valsartan 103 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 10 mg
Study: 10333347
Drug: valsartan 40
Normalized name: valsartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 40 mg
Study: 7795831
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of weight loss and sodium reduction
Study: 19614621
Drug: Masitinib (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib (3, 4.5, and 6 mg/kg/day)
Study: 17968637
Drug: Tibetan medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibetan medicine
Study: 15311147
Drug: Telmisartan (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40-80 mg)
Study: 15311147
Drug: Telmisartan (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40-80 mg) after missed dose
Study: 15311147
Drug: Valsartan (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80-160 mg)
Study: 15311147
Drug: Valsartan (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80-160 mg) after missed dose
Study: 9501889
Drug: Sertraline during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline during the luteal phase
Study: 31645364
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of a web-based decision support tool for antidepressant treatment
Study: 26842902
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily for CrCl ≥ 50 ml/min or 7.5 mg once daily for CrCl ≥ 30 ml/min and < 50 ml/min for 45 days
Study: 24576226
Drug: Recombinant follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle-stimulating hormone (rFSH)
Study: 31575059
Drug: Low-dose POP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose POP (8.7 mg/d)
Study: 31575059
Drug: Medium-dose POP
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose POP (15.2 mg/d)
Study: 31575059
Drug: High-dose POP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose POP (37.2 mg/d)
Study: 19483236
Drug: Translocation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Translocation of the proximal nerve stump into an adjacent subcutaneous vein
Study: 15562051
Drug: Selective spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective spinal anesthesia (SSA) with 4 mg of hyperbaric bupivacaine
Study: 7542301
Drug: Miconazole and
Normalized name: Miconazole and zinc oxide only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole and G-CSF administered simultaneously (Group I)
Study: 7542301
Drug: Miconazole administered
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole administered later during G-CSF administration (Group II)
Study: 7542301
Drug: Only miconazole
Normalized name: Product containing only miconazole (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only miconazole administered (Group III)
Study: 7542301
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with neutrophil counts <500/microliters throughout miconazole administration (Group I)
Study: 7542301
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with neutrophil counts <500/microliters throughout miconazole administration (Group II)
Study: 28170282
Drug: Diskus (600 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diskus (600 μg dose)
Study: 28170282
Drug: MDI (600 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI (600 μg dose)
Study: 23839182
Drug: Doxycycline calcium
Normalized name: Doxycycline Calcium
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline calcium 0.6 mg/kg/day
Study: 23839182
Drug: Doxycycline calcium
Normalized name: Doxycycline Calcium
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline calcium 1.2 mg/kg/day
Study: 23839182
Drug: Doxycycline calcium
Normalized name: Doxycycline Calcium
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline calcium 2.4 mg/kg/day
Study: 21216540
Drug: Porcilis PCV(®)
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcilis PCV(®) vaccine, 2 mL intramuscular dose
Study: 21216540
Drug: Diluvac Forte(®)
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluvac Forte(®) adjuvant, 2 mL intramuscular dose
Study: 17548839
Drug: XELOX (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX (oral capecitabine 1,000 mg/m2 bid for 14 days plus oxaliplatin 130 mg/m2 on day 1 every 3 weeks)
Study: 17548839
Drug: FUOX (continuous‐infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUOX (continuous‐infusion FU 2,250 mg/m2 during 48 hours on days 1, 8, 15, 22, 29, and 36 plus oxaliplatin 85 mg/m2 on days 1, 15, and 29 every 6 weeks)
Study: 11322176
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg twice daily for 4 days
Study: 7943103
Drug: Prophylactic amnioinfusion
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic amnioinfusion (600 ml saline solution bolus followed by 3 ml/min)
Study: 3307517
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.01 mg/kg atropine sulphate
Study: 21704238
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 300 mg (test formulation)
Study: 21704238
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 300 mg (reference formulation)
Study: 19319953
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg dose of inactivated influenza vaccine
Study: 19319953
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg dose of inactivated influenza vaccine
Study: 19319953
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg dose followed by 15 microg booster
Study: 19319953
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg dose followed by placebo
Study: 19319953
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg dose followed by placebo
Study: 9021380
Drug: 3-monthly depot
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-monthly depot leuprolide
Study: 9021380
Drug: Monthly depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly depot leuprolide
Study: 1425865
Drug: lansoprazole 10
Normalized name: lansoprazole 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 10 mg
Study: 1425865
Drug: lansoprazole 20
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lansoprazole 20 mg
Study: 1425865
Drug: lansoprazole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole (all doses) after 7 days
Study: 6438679
Drug: High-nicotine cigarette
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-nicotine cigarette (1.38 mg) (Experiment III)
Study: 6438679
Drug: Low-nicotine cigarette
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-nicotine cigarette (0.40 mg) (Experiment III)
Study: 27213441
Drug: DER-diet (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: DER-diet (synthetic diet containing daily energy requirements)
Study: 17474991
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 11 vitamins and 5 minerals for 12 months
Study: 17474991
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken daily for 12 months
Study: 15052846
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment consisting of postisometric relaxation, massage of the prostate, and transrectal mobilization of the pelvic ligaments
Study: 11344184
Drug: rhGH (Saizen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (Saizen, Serono, Switzerland) 0.09 IU/kg body weight (BW) 3 times weekly with dietary intervention
Study: 2736877
Drug: Lipid-supplemented group
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-supplemented group (one-quarter of glucose energy replaced by intravenous fat)
Study: 31550819
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive surgery for rectal GISTs
Study: 31550819
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment of GIST
Study: 25919773
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (CT) - rabeprazole-amoxicillin-clarithromycin-metronidazole for 14 days; n=122
Study: 25919773
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (QT) - rabeprazole-tetracycline-metronidazole-colloidal bismuth subcitrate for 10 days; n=97
Study: 25919773
Drug: Levofloxacin-based therapy
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based therapy (LT) - rabeprazole-amoxicillin-levofloxacin for 10 days; n=87
Study: 23731454
Drug: 1072 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1072 nm infrared light therapy
Study: 23731454
Drug: Placebo (sham)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham) light therapy
Study: 19372480
Drug: Clear liquid
Normalized name: Ensure Clear Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear liquid gastric emptying study (300 mL of water with 7.4 MBq [0.2 mCi] of (111)In-diethylenetriaminepentaacetic acid), 30-min duration
Study: 10883416
Drug: AMP 579
Normalized name: psyllium 579 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP 579 (50 micrograms/kg as a 6-hour constant-rate intravenous infusion)
Study: 3782621
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methylphenidate and cognitive therapy
Study: 3782621
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication during post‐testing)
Study: 24947950
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg I/V metronidazole and 1 g Ceftriaxone I/V before induction of anesthesia
Study: 19087155
Drug: Subcutaneous histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous histamine (1-10 ng twice a week)
Study: 19087155
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (50 U, one injection cycle)
Study: 12548308
Drug: PABA15 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: PABA15 (80 mg at 08:00, 12:00, and 15:00)
Study: 12548308
Drug: PABA18 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: PABA18 (80 mg at 08:00, 12:00, and 18:00)
Study: 12548308
Drug: Single dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dosage of 80 mg PABA
Study: 12548308
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg PABA at recommended hours
Study: 12548308
Drug: Recommended dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dosage schedule (PABA taken with main meals)
Study: 10700656
Drug: Amitriptyline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline treatment for 6 weeks
Study: 9568324
Drug: Trypsin: chymotrypsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trypsin: chymotrypsin preparation
Study: 3017804
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (1 g daily enema)
Study: 3017804
Drug: Prednisolone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (25 mg daily enema)
Study: 24687506
Drug: Liposomal amikacin
Normalized name: amikacin liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal amikacin for inhalation (LAI) 560 mg
Study: 21144224
Drug: Steroid-infused carboxymethylcellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-infused carboxymethylcellulose (CMC) foam, 4 mL hydrated with triamcinolone, 40 mg/mL (Kenalog 40)
Study: 16430197
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from protease inhibitors to efavirenz and from stavudine to tenofovir at baseline (Group 1)
Study: 16430197
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from protease inhibitors to efavirenz and from stavudine to tenofovir at week 24 (Group 2)
Study: 6336918
Drug: Intravenous cefoxitin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefoxitin in conjunction with standard bowel preparation
Study: 6336918
Drug: Standard bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bowel preparation
Study: 19733660
Drug: gelatin capsules
Normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin capsules loaded with fast‐disintegrating starch pellets (group P)
Study: 19733660
Drug: lyophilized lactose/skimmed
Approvals — FDA: no, EMA: no, PMDA: no
Description: lyophilized lactose/skimmed milk (group L)
Study: 19733660
Drug: all groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all groups (P, L, C)
Study: 12601075
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin (target INR, 1.5 to 2.0)